Welcome, visitor! [ Register | Login


Ibrutinib treatment-Medicine for chronic lymphocytic leukemia

ibrutinib (1)


Ibrutinib may be responsible for causing fetal harm when administered to pregnant women. Women are apprised of the potential risk to a fetus and to avoid pregnancy during treatment and for one month following cessation of the therapy. It offers higher RR in comparison to the other therapies for identical sorts of lymphoma.
Ibrutinib specifically is FDA approved in order to treat chronic lymphocytic leukemia (CLL) and mantle cell lymphoma patients who have taken treatment at least one earlier therapy. The Ibrutinib cost depends according to different wholesalers and brands in the market.

No Tags

6 total views, 1 today


Listing ID: 4146140493db6ac0

Report problem

Processing your request, Please wait....
Si prega di attivare i Javascript! / Please turn on Javascript!

Javaskripta ko calu karem! / Bitte schalten Sie Javascript!

S'il vous plaît activer Javascript! / Por favor, active Javascript!

Qing dakai JavaScript! / Qing dakai JavaScript!

Пожалуйста включите JavaScript! / Silakan aktifkan Javascript!